SThree

  • ISIN: GB00B0KM9T71
  • Land: Großbritannien

Nachricht vom 10.06.2021 | 14:40

SThree: Director/PDMR Shareholding

SThree (STEM)
10-Jun-2021 / 13:40 GMT/BST
Dissemination of a Regulatory Announcement that contains inside information according to REGULATION (EU) No 596/2014 (MAR), transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1. Details of the person discharging managerial responsibilities / person closely associated

 

a) Names

 

Alex Smith

2. Reason for the notification

 

a) Position/status

 

 

CFO

 

b) Initial notification /Amendment

 

Initial notification

3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a) Name

SThree plc

b) LEI

 

2138003NEBX5VRP3EX50

4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a) Description of the financial instrument, type of instrument

Identification code

 

Ordinary shares of 1p

GB00B0KM9T71

b) Nature of the transaction

 

 

Purchase of shares under the Dividend Reinvestment Plan for the SIP

 

c) Price(s) and volume(s)

 

Purchase of shares under the Dividend Reinvestment Plan for the SIP

 

Names

 

Alex Smith

 

Price(s)

 

463p

Volume(s)

 

133

 

d) Aggregated information

- Aggregated volume

- Price

N/A

e) Date of the transaction

 

04/06/2021

f) Place of the transaction

London Stock Exchange

 




show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Infineon Technologies AG: Aufsichtsrat beruft Jochen Hanebeck zum Nachfolger von Dr. Reinhard Ploss als Vorstandsvorsitzenden von Infineon

25. November 2021, 17:45

Aktuelle Research-Studie

3U HOLDING AG

Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten

26. November 2021